Hai-Ping Dai

National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University

Affiliated withThe First Affiliated Hospital of Soochow University Soochow University

Research Area

Biography

Hai-Ping Dai has not added Biography.
If you are Hai-Ping Dai and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia. Acta haematologica\| PubMed ID: 19246886	2008
LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation. Genes, chromosomes & cancer\| PubMed ID: 19760607	2009
[Establishment and characterization of a new human myeloid leukemia cell line SH-2]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 19954598	2009
[The different signal patterns of two FISH probes in the FISH detection of Ph-positive leukemia and their clinical significance]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics\| PubMed ID: 20376798	2010
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16). International journal of hematology\| PubMed ID: 23054652	2012
[Correlation between expression of SIL-TAL1 fusion gene and deletion of 6q in T-cell acute lymphoblastic leukemia]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 25543465	2014
Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion. Journal of hematology & oncology\| PubMed ID: 26293203	2015
[Effect of LPXN Overexpression on the Proliferation, Adhesion and Invasion of THP-1 Cells and Its Mechamisms]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 28641616	2017
MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. Upsala journal of medical sciences\| PubMed ID: 29493383	2018
Effects of preemptive interferon-α monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study. Annals of hematology\| PubMed ID: 29995264	2018
Downregulation of LPXN expression by siRNA decreases the malignant proliferation and transmembrane invasion of SHI-1 cells. Oncology letters\| PubMed ID: 30655748	2019
Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With Fusion. Frontiers in oncology\| PubMed ID: 32266142	2020
Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53. Leukemia research reports\| PubMed ID: 33194542	2020
Identification of as a Novel Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia. Frontiers in oncology\| PubMed ID: 33505919	2020
A Recurrent Cryptic Rearrangement in an Adult Patient With Mixed-Phenotype Acute Leukemia, T/myeloid, NOS. Frontiers in oncology\| PubMed ID: 34367969	2021
MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation. OncoTargets and therapy\| PubMed ID: 34744437	2021
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. Biomarker research\| PubMed ID: 35130959	2022
Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. American journal of cancer research\| PubMed ID: 35261791	2022
Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. American journal of hematology\| PubMed ID: 36219502	2023
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematological oncology\| PubMed ID: 36251458	2023
Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia. Frontiers in oncology\| PubMed ID: 36313659	2022
CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL. Biomarker research\| PubMed ID: 36793095	2023
Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. Annals of hematology\| PubMed ID: 37103615	2023
Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration. Frontiers in immunology\| PubMed ID: 37143650	2023
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of hematology\| PubMed ID: 37227492	2023
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. British journal of haematology\| PubMed ID: 37246158	2023
Long-term follow-up of tandem CD19/CD22 CAR T-Cells in r/r B-ALL patients with high-risk features. American journal of hematology\| PubMed ID: 37665759	2023
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. Blood cancer journal\| PubMed ID: 38012154	2023
Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. Clinical case reports\| PubMed ID: 38084356	2023
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study. Blood cancer journal\| PubMed ID: 38238305	2024
Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia. HemaSphere\| PubMed ID: 38435426	2024
Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study. Leukemia research\| PubMed ID: 38493755	2024
Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements. Annals of hematology\| PubMed ID: 38990294	2024
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based ... Blood cancer journal\| PubMed ID: 39179571	2024
Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia. Nature communications\| PubMed ID: 39294124	2024
Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia. HemaSphere\| PubMed ID: 39380843	2024
Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations. Bone marrow transplantation\| PubMed ID: 39658655	2025
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma. Annals of hematology\| PubMed ID: 39692783	2025
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood\| PubMed ID: 40009498	2025
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial. Journal of hematology & oncology\| PubMed ID: 40329358	2025
Adult AML with NUP98 rearrangements should be stratified into adverse-risk group. Blood cancer journal\| PubMed ID: 40603849	2025
Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-mat... Leukemia & lymphoma\| PubMed ID: 41048093	2025
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT. Clinical epigenetics\| PubMed ID: 41084078	2025
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial. Blood cancer journal\| PubMed ID: 41145445	2025
A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Phi... Cancer\| PubMed ID: 41199560	2025
[A Study of Flow Sorting Lymphocyte Subsets to Detect Epstein-Barr Virus Reactivation in Patients with Hematological Malignancies]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 41234101	2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study... Haematologica\| PubMed ID: 41307138	2025
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology\| PubMed ID: 41338863	2025
Coexistence of with fusion in an adult patient with acute B-lymphoblastic leukemia. Leukemia & lymphoma\| PubMed ID: 41635094	2026